600165 *ST宁科生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)667.510-116.790-20.217-19.2402.250
总资产报酬率 ROA (%)-15.708-14.929-4.298-5.0020.749
投入资产回报率 ROIC (%)-29.958-23.967-6.126-6.6130.774

边际利润分析
销售毛利率 (%)-10.552-34.93011.112-32.9349.223
营业利润率 (%)-380.292-173.002-23.775-74.8612.226
息税前利润/营业总收入 (%)-317.807-131.109-11.173-62.63836.110
净利润/营业总收入 (%)-388.240-180.667-24.974-76.16619.478

收益指标分析
经营活动净收益/利润总额(%)29.02460.97489.96993.760-206.382
价值变动净收益/利润总额(%)55.973-6.619-21.092-21.262208.018
营业外收支净额/利润总额(%)2.0094.2952.2970.45986.789

偿债能力分析
流动比率 (X)0.2480.1100.1610.2890.630
速动比率 (X)0.1920.0570.0910.1550.560
资产负债率 (%)103.94387.08472.73167.82261.827
带息债务/全部投入资本 (%)75.79057.31146.67940.677--
股东权益/带息债务 (%)-34.19217.24961.65677.84488.936
股东权益/负债合计 (%)-11.5766.51826.39034.35846.377
利息保障倍数 (X)-4.522-2.640-0.849-4.9841.875

营运能力分析
应收账款周转天数 (天)71.13456.53713.79547.1130.000
存货周转天数 (天)147.09695.78975.598122.2670.000